<DOC>
	<DOCNO>NCT02707107</DOCNO>
	<brief_summary>Study evaluate safety , tolerability pharmacokinetics multiple escalate dos intravenous WCK 5222 ( Zidebactam Cefepime ) healthy adult human subject .</brief_summary>
	<brief_title>MED Study Evaluate Safety , Tolerability Pharmacokinetics Intravenous WCK 5222 ( Zidebactam Cefepime ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cefepime</mesh_term>
	<criteria>1 . Have body mass index 18 30 kg/m2 ( inclusive ) calculate weight ( kg ) /height ( m2 ) . 2 . Resting supine blood pressure 90 139 ( systolic ) /40 89 ( diastolic ) mmHg rest pulse rate 40 100 beat per minute . 3 . Calculated creatinine clearance â‰¥80 mL/min ( CockcroftGault method ) . 4 . All value hematology , serum chemistry , coagulation , urinalysis show clinically significant deviation normal judge Principal Investigator . 1 . Participation another investigational drug device study treat investigational product within 30 day 5 halflives , whichever longer , investigational product administration study . 2 . History/evidence clinically relevant pathology relate cardiovascular system , central nervous system , respiratory tract , gastrointestinal tract , endocrinology , immunology , hematology systemic disorder/major surgery , opinion Principal Investigator would confound subject 's participation followup study . 3 . History clinically significant food drug allergy , include know hypersensitivity cefepime relate drug . 4 . History Clostridium difficile induce diarrhea infection within 1 year screening . 5 . Prior exposure zidebactam .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>